Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Delstrigo - SFDA Drug Approval Details

Approvals/SFDA/Delstrigo

Authorized

NCE

Delstrigo

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: 4661457734b8d4e7
Company: Unknown
Type: NCE

Approval Details

Approval Id: 4661457734b8d4e7
Drug Approval Sfda Name: Delstrigo
Trade Name: Delstrigo
Generic Name: DORAVIRINE,LAMIVUDINE,TENOFOVIR DISOPROXIL
Register Number: 1612223019
Register Year: 2022
Drug Type: NCE
Route Of Administration: Oral use
Package Type: Tablet Container
Package Size: 30
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: do not store above 30°c
Shelf Life: 24 Months
Distribution Site: Pharmacy
Description Code: 21000004548-645-100000073665
Price: 2413.85

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

4661457734b8d4e7

Type

NCE

Back to SFDA Approvals